Research progress of radical chemoradiotherapy combined with immunotherapy in locally advanced esophageal carcinoma
10.3760/cma.j.cn101721-20240403-00106
- VernacularTitle:根治性放化疗联合免疫治疗在局部晚期食管癌中的研究进展
- Author:
Huizhu CHEN
1
;
Jiayan CHEN
;
Xianshu GAO
Author Information
1. 北京大学第一医院放射治疗科，北京 100034
- Keywords:
Esophageal carcinoma;
Locally advanced;
Radical chemoradiotherapy;
Immunotherapy
- From:
Clinical Medicine of China
2024;40(4):241-248
- CountryChina
- Language:Chinese
-
Abstract:
Radical chemoradiotherapy is the standard treatment for unresectable locally advanced esophageal carcinoma, but its efficacy needs to be further improved, and combined immunotherapy is a potential direction to solve this issue. At present, the combination of radical radiotherapy and chemotherapy with immunotherapy mainly includes three modes: induction chemotherapy combined with immunotherapy before radiotherapy and chemotherapy, concurrent immunotherapy during radiotherapy and chemotherapy, and immune maintenance therapy after radiotherapy and chemiotherapy. A number of phase I and Ⅱ clinical trials have shown that radiotherapy and chemotherapy combined with immunotherapy can be tolerated by patients with good clinical efficacy, and more research data and long-term follow-up results are expected. At the same time, the adverse reactions caused by immunotherapy still deserve attention. Finding the optimal combination therapy mode, screening the patient population suitable for the treatment mode, and predicting and identifying serious adverse reactions as early as possible are the directions that need to be explored continuously.
